1stOncology™: Cancer Intelligence Service – Page 8562 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021

On August 31, 2021 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2021, which is being held from September 16-21, 2021 (Press release, Phio Pharmaceuticals, AUG 31, 2021, View Source [SID1234587047]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details are as follows:

Event:

ESMO Virtual Congress 2021

Title:

Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors

Authors:

Benjamin Cuiffo, et al.

Abstract Number:

#4154

Date:

September 16-21, 2021

An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company’s website (click here)

Intellia Therapeutics to Present at September Healthcare Investor Conferences

On August 31, 2021 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported that it will present at the following virtual healthcare investor conferences in September (Press release, Intellia Therapeutics, AUG 31, 2021, View Source [SID1234587046]):

Thursday, September 9, 2021
Wells Fargo Healthcare Conference
Time: 10:40 am ET

Monday, September 13, 2021
H.C. Wainwright 23rd Annual Global Investment Conference
Time: 7:00 am ET

A live webcast of Intellia’s presentations at these events will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each presentation.

IMMUTEP’S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE

On August 31, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Company") reported to advise its Chinese partner for eftilagimod alpha ("efti" or "IMP321"), EOC Pharma ("EOC") is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China (Press release, Immutep, AUG 31, 2021, View Source [SID1234587045]).

EOC is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial is expected to commence in the first half of calendar year 2022.

The new trial builds on the latest promising data presented by Immutep at ASCO (Free ASCO Whitepaper) 2021 and on EOC’s previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients. This previously announced Phase II trial is currently expected to commence in the second half of calendar year 2021.

In addition, EOC has partnered with a contract development and manufacturing organisation in China. In August 2020, EOC received positive feedback from the Centre for Drug Evaluation (CDE), subordinate unit of China’s National Medical Products Administration (NMPA) on its CMC comparability study results and recently completed an important 2000L manufacturing step for efti.

Dr. Xiaoming Zou, CEO of EOC Pharma, commented: "Encouraged by our partner Immutep’s exciting clinical performance, we are ready to further exploit the clinical benefits of this promising drug in the IO realm."

Commenting on EOC’s plans, Immutep CEO Marc Voigt said: "It is great to see our growing confidence in efti is shared by our Chinese partner, EOC. Like Immutep, EOC is expanding its clinical trial pipeline, adding a new combination therapy study of efti with an anti-PD-1 drug. This is the same promising concept we are evaluating in TACTI-002 and TACTI-003, for example."

Efti is exclusively licensed to EOC for the territory of Greater China. EOC has full responsibility for the development and commercialisation of efti in the territory, and Immutep is eligible to receive development-based milestone payments and sales-based royalties.

Immunophotonics Switzerland (IPS Biopharma) Invited to Present at Swiss Biotech Day

On August 31, 2021 Immunophotonics Switzerland (IPS Biopharma) reported that it will be presenting at the Swiss Biotech Day in the Emerging Company session hosted by BB Pureos Bioventures (Press release, Immunophotonics, AUG 31, 2021, View Source [SID1234587044]). The Swiss Biotech Day is one of the premier annual biotechnology conferences in Europe, featuring panel discussions and presentations from key opinion leaders in the biotech industry. Immunophotonics’ presentation will take place on Tuesday, September 7, 2021, in Basel, Switzerland. For more information on the program and how you can attend, please click here.

HebeCell Raises $53 Million in Series A Financing to Advance Unique Off-The-Shelf PSC-CAR-NK Products Into Clinics

On August 31, 2021 HebeCell Corp ("HebeCell") reported that it has successfully closed a US$53 million Series A financing to advance its unique off-the-shelf pluripotent stem cell (PSC)-CAR-NK products into clinics (Press release, HebeCell, AUG 31, 2021, View Source [SID1234587043]). This strategic investment is led by Jacobio Pharmaceuticals ("Jacobio" 1167.HK), who will collaborate with HebeCell to develop the next-generation PSC-CAR-NK therapy for cancer, viral infection, and autoimmune diseases.

Capital from this financing will be used to accelerate HebeCell’s R&D program, IND filing, clinical application, and marketing as the company grows its operations both in the US domestically and internationally. It will also help HebeCell expand globally and gain international presence in the NK cell therapy industry.

"This Series A round financing is crucial in transforming HebeCell from a start-up into a clinical stage company," said Dr. John Lu, CEO of HebeCell. "And it further validates the value of HebeCell’s next-generation technology platform which is truly disruptive to the industry. We are very eager to work with Jacobio and all the investors and partners to strengthen the technology and bring products to market using our platform."

"The establishment of a master PSC-CAR cell bank targeting multiple specific antigens will provide inexhaustible cell sources for the manufacture of truly off-the-shelf CAR-NK cells for all patients," said Dr. Allen Feng, CSO of HebeCell. "The unique complementary strengths and resources between HebeCell and Jacobio will alter the NK cell therapy field by delivering cost effective allogeneic products worldwide and achieve the unmet needs in the Immuno-Oncology."

"Cell therapy is at the forefront of cancer therapy. We have long focused on revolutionary and innovative therapies," said Dr. Wang Yinxiang, CEO of Jacobio. "We have strong ability and know-how on drug R&D of small molecule and antibody, with the partnership with HebeCell in place, we plan to add the allogeneic cell therapy into our pipelines in a move to explore the clinical value of a combination therapy with our existing products."

HebeCell is currently recruiting R&D and GMP scientists and other positions. See link for more information: View Source